Significant biosimilar activities this week include 15 Nov 20 | US | Genentech filed a complaint against Centus...
Pearce IP BioBlast™: w/e 20 November 2020
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast™: w/e 13 November 2020
Significant biosimilar activities this week include 05 Nov 20 | Formycon announced its BLA resubmission strategy for...
Pearce IP BioBlast™: w/e 06 November 2020
Significant biosimilar activities this week include 05 Nov 20 | Teva released its Q3 2020 financial results, reporting...
Pharma Intelligence announces Global Generics & Biosimilars Digital Awards Winners
Pharma Intelligence announced the Global Generics & Biosimilars Digital Awards Winners. Alvogen, Accord...
Pearce IP BioBlast™: w/e 30 October 2020
Significant biosimilar activities this week include 22 Oct 20 | Ph III clinical trials of FYB202...
Pearce IP BioBlast™: w/e 23 October 2020
Significant biosimilar activities this week include 15 Oct 20 | Henlius and Essex announced they have entered into a...
Pearce IP BioBlast™: w/e 16 October 2020
Significant biosimilar activities this week include 09 Oct 20 | CN | Innovent and Eli Lilly jointly announced China's...
Pearce IP BioBlast™: w/e 09 October 2020
Significant biosimilar activities this week include 05 Oct 20 | Medicure announced it has entered a License,...
Pearce IP BioBlast™: w/e 02 October 2020
Significant biosimilar activities this week include 28 Sep 20 | Innovent announced its Ph III trial of Byvasda®...
TGA Approves Second Registered Medicinal Cannabis Product
The TGA has approved GW Pharma's Epidyolex® (cannabidiol) as an adjunctive therapy for seizures associated with...
Pearce IP BioBlast™: w/e 25 September 2020
Significant biosimilar activities this week include 21 Sep 20 | EU | Alexion announced it has received a positive...
Pearce IP BioBlast™: w/e 18 September 2020
Significant biosimilar activities this week include 14 Sep 20 | Novartis announced the results of Ph III trials of...
Pearce IP BioBlast™: w/e 11 September 2020
Significant biosimilar activities this week include 08 Sep 20 | The Centre for Biosimilars reports a new study...
Pearce IP BioBlast™: w/e 04 September 2020
Significant biosimilar activities this week include 31 Aug 20 | US | Mylan and Biocon announced the launch of Semglee®...
Pearce IP BioBlast™: w/e 28 August 2020
Significant biosimilar activities this week include 24 Aug 20 | JP | Merck announced Keytruda® (pembrolizumab) has...
Pearce IP BioBlast™: w/e 21 August 2020
Significant biosimilar activities this week include 11 Aug 20 | In an online press conference, Samsung Biologics...